Vicente Valero

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Managing ixabepilone adverse events with dose reduction
    Vicente Valero
    Department of Breast Medical Oncology, Division of Cancer Medicine, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 13:1-6. 2013
  2. doi request reprint Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials
    Vicente Valero
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 12:240-6. 2012
  3. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
  4. pmc Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
  5. doi request reprint Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeu
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:149-56. 2011
  6. ncbi request reprint Primary chemotherapy with docetaxel for the management of breast cancer
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:35-43. 2002
  7. ncbi request reprint Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 3:S63-8. 2002
  8. pmc CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
  9. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
  10. ncbi request reprint Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:4691-9. 2004

Collaborators

Detail Information

Publications114 found, 100 shown here

  1. doi request reprint Managing ixabepilone adverse events with dose reduction
    Vicente Valero
    Department of Breast Medical Oncology, Division of Cancer Medicine, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 13:1-6. 2013
    ..More information is required on dosage and scheduling of ixabepilone in combination with other agents, including novel targeted therapies...
  2. doi request reprint Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials
    Vicente Valero
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 12:240-6. 2012
    ..This retrospective analysis aimed to determine whether early dose reduction impacts the efficacy of ixabepilone plus capecitabine in women with metastatic breast cancer (MBC)...
  3. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
    ..We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients...
  4. pmc Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
    ....
  5. doi request reprint Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeu
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:149-56. 2011
    ..Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC...
  6. ncbi request reprint Primary chemotherapy with docetaxel for the management of breast cancer
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:35-43. 2002
    ..Preliminary results have shown that incorporation of docetaxel can improve the rate of breast preservation surgery and the overall clinical and pathologic complete response rates...
  7. ncbi request reprint Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience
    Vicente Valero
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 3:S63-8. 2002
    ..The history of clinical trials focusing on primary therapy in breast cancer at the M. D. Anderson Cancer Center will be reviewed...
  8. pmc CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  9. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  10. ncbi request reprint Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:4691-9. 2004
    ..To evaluate the efficacy of radiation in patients treated with neoadjuvant chemotherapy and mastectomy...
  11. ncbi request reprint Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:351-7. 2005
    ..To identify the clinical and pathologic factors predictive of locoregional recurrence (LRR) after neoadjuvant chemotherapy, mastectomy, and radiotherapy...
  12. ncbi request reprint Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1337-42. 2004
    ..We retrospectively studied whether Her2/neu-positive disease was associated with locoregional recurrence (LRR) after postmastectomy radiotherapy (RT) for breast cancer...
  13. ncbi request reprint Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4107-15. 2006
    ..D. Anderson Cancer Center (Houston, TX)...
  14. pmc Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer
    Roshan Agarwal
    The University of Texas M D Anderson Cancer Center MDACC, Houston, Texas, USA
    Clin Cancer Res 15:3654-62. 2009
    ..We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling...
  15. doi request reprint Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
    Ricardo H Alvarez
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:1210-7. 2010
    ....
  16. ncbi request reprint Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:1037-44. 2006
    ..To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR)...
  17. pmc Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
    ....
  18. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  19. ncbi request reprint T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy
    Amit K Garg
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:138-45. 2004
    ..To help define the clinical and pathologic predictors of locoregional recurrence (LRR) in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy without radiotherapy for early-stage disease...
  20. doi request reprint Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer
    Catherine M Kelly
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 30:930-5. 2012
    ..We investigated whether capecitabine and docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) or weekly paclitaxel (WP) followed by FEC would improve relapse-free survival (RFS) in operable breast cancer...
  21. ncbi request reprint Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  22. ncbi request reprint Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  23. ncbi request reprint Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...
  24. doi request reprint Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  25. ncbi request reprint Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1436-44. 2007
    ..The authors compared the prognostic features of IBC and non-IBC locally advanced breast cancer (LABC) to gain insight into the biology of this disease entity...
  26. pmc Genomic grade index is associated with response to chemotherapy in patients with breast cancer
    Cornelia Liedtke
    DPhil, Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:3185-91. 2009
    ....
  27. doi request reprint Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
    Yesim Eralp
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
    J Cancer Res Clin Oncol 135:141-8. 2009
    ..The aim of this study is to evaluate the impact of body mass index (BMI) and various prognostic factors on pathologic response and survival in young patients with localized breast cancer...
  28. ncbi request reprint Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1348-54. 2006
    ..A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer...
  29. pmc Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results
    Banu K Arun
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1527-34. 2011
    ....
  30. ncbi request reprint Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
    W Fraser Symmans
    Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 25:4414-22. 2007
    ..To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response...
  31. ncbi request reprint Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer
    Eugene Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:1225-33. 2002
    ..To assess the therapeutic outcomes and treatment-related morbidity of patients treated with radiation for inoperable breast cancer resistant to anthracycline-containing primary chemotherapy...
  32. doi request reprint Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 12:264-9. 2012
    ....
  33. pmc PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 10:R27. 2008
    ..In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer...
  34. ncbi request reprint Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 104:1158-71. 2005
    ..An analysis of prognostic factors for these patients also is presented...
  35. ncbi request reprint A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:935-44. 2006
    ....
  36. ncbi request reprint Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:9304-11. 2005
    ..The purpose of this study was to determine long-term outcome in patients achieving pCR of cytologically proven axillary lymph node (ALN) metastases...
  37. doi request reprint Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1455-61. 2008
    ..The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and more efficacious...
  38. pmc A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301438, Houston, TX 77030, USA
    Cancer 116:814-21. 2010
    ..This study was performed to compare efficacy and toxicity profiles of paclitaxel using 3-hour versus 96-hour infusion schedules...
  39. pmc Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 69:4116-24. 2009
    ..PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets...
  40. ncbi request reprint Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3249-54. 2003
    ..We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer...
  41. doi request reprint Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1439, USA
    Clin Cancer Res 16:1904-14. 2010
    ..This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)...
  42. ncbi request reprint Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes
    Massimo Cristofanilli
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 23:41-8. 2005
    ..To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome...
  43. ncbi request reprint Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 106:2327-36. 2006
    ..After a median follow-up of 6.5 years, no significant differences were observed in recurrence-free survival (RFS) or overall survival (OS) between the 2 arms. This report updates the survival analyses...
  44. ncbi request reprint Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  45. ncbi request reprint Women age < or = 35 years with primary breast carcinoma: disease features at presentation
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2466-72. 2005
    ..The purpose of the current study was to describe a population of young patients with breast carcinoma, their characteristics at the time of diagnosis, and the association of these characteristics with disease recurrence and survival...
  46. doi request reprint Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs
    Gary V Walker
    Department of Radiation Oncology, The Morgan Welch Inflammatory Breast Cancer Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 83:1381-6. 2012
    ..The purpose of this study was to define how pretreatment PET/CT studies affected postmastectomy radiation treatment (PMRT) planning decisions for IBC...
  47. doi request reprint Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer
    Merih Guray Durak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 17:462-9. 2011
    ..Age at diagnosis and associated FCC are significant factors in predicting recurrence in patients with T1a,bN0 IBC. Adjuvant systemic therapy should be discussed with and considered for young patients with T1a,bN0 IBC...
  48. ncbi request reprint A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer
    Jonathan C Trent
    Departments of Sarcoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2426-34. 2003
    ..For Phase II, the purpose was to determine the safety and efficacy of this combination as first-line treatment in patients with metastatic breast cancer (MBC)...
  49. ncbi request reprint Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1000-6. 2006
    ..The purpose of the current study was to determine long-term outcome in patients achieving a pCR of cytologically proven inflammatory breast carcinoma ALN metastases after primary chemotherapy...
  50. pmc High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:5700-6. 2009
    ..To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) -positive breast cancer...
  51. ncbi request reprint A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer
    Sharon H Giordano
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3360-8. 2002
    ..This Phase II study was designed to determine the efficacy and toxicity of combination doxorubicin and paclitaxel as front-line treatment for metastatic breast cancer...
  52. ncbi request reprint Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ophthalmology 109:1188-91. 2002
    ..To compare the frequency of canalicular stenosis as a side effect of weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer...
  53. ncbi request reprint Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1073-9. 2002
    ..In this prospective randomized trial, the role of paclitaxel was evaluated in an adjuvant setting to determine its impact on reducing the risk of recurrence in patients with operable breast cancer...
  54. doi request reprint Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule
    Fadi Estephan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Tex, USA
    Oncology 77:63-70. 2009
    ..A phase I study was initiated to determine the maximum tolerated dose (MTD) of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic breast carcinoma (MBC)...
  55. doi request reprint Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Breast Cancer 8:516-21. 2008
    ....
  56. ncbi request reprint Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women
    Wei Tse Yang
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77230, USA
    Breast Cancer Res Treat 111:405-10. 2008
    ..The aim of this study was to compare the mammographic breast density, visibility, and tumor features of different breast cancer immunophenotypes...
  57. ncbi request reprint Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:7098-104. 2005
    ..To identify clinicopathological factors predictive of distant metastasis in patients who had a pathologic complete response (pCR) after neoadjuvant chemotherapy (NC)...
  58. ncbi request reprint The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
    Alberto J Montero
    Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:229-35. 2005
    ..The purpose of the current study, performed retrospectively, was to characterize the natural history of this subset of patients, both before and after the advent of adjuvant anthracycline-based chemotherapy and tamoxifen...
  59. ncbi request reprint Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy
    Jeannie Shen
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 11:854-60. 2004
    ..This study was conducted to assess the outcome of a carefully selected group of patients who presented with breast cancer involving the skin and who had breast conservation therapy (BCT) following neoadjuvant chemotherapy...
  60. doi request reprint Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
    Takayuki Iwamoto
    Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 125:785-95. 2011
    ..IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC...
  61. ncbi request reprint Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy
    Bita Esmaeli
    Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:504-7. 2003
    ..The current study was conducted to report the severity and management of canalicular and nasolacrimal duct stenosis as a side effect of docetaxel therapy and to report the outcomes of surgical intervention for this condition...
  62. ncbi request reprint Squamous cell carcinoma of the breast
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7827-35. 2005
    ..D. Anderson Cancer Center (Houston, TX) and a series of 137 patients identified through the Surveillance, Epidemiology, and End Results (SEER) database to make therapy recommendations...
  63. ncbi request reprint A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
    Cancer 98:900-7. 2003
    ..The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline-resistant and taxane-resistant, metastatic breast carcinoma...
  64. ncbi request reprint Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:2321-6. 2002
    ....
  65. doi request reprint Ixabepilone for the treatment of breast cancer
    Ricardo H Alvarez
    Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center Houston, USA
    Ann Med 43:477-86. 2011
    ..The clinical activity of ixabepilone combined with bevacizumab for advanced breast cancer was very promising...
  66. doi request reprint Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome
    Yun Gong
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:5476-84. 2011
    ..In this retrospective study, the authors examined EZH2 expression in IBC tumors and evaluated the relation between EZH2 expression and patient survival...
  67. pmc Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer
    Mariana Chavez-MacGregor
    Divison of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 118:326-32. 2012
    ..In the current study, the authors sought to evaluate whether the use of bisphosphonates increased the rate of pathological complete response (pCR) in patients with breast cancer...
  68. pmc Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity
    Mariana Chavez-MacGregor
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 116:4168-77. 2010
    ..The current study was conducted to evaluate the influence of race/ethnicity and tumor subtype in pathologic complete response (pCR) following treatment with neoadjuvant chemotherapy...
  69. ncbi request reprint Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma
    Emer O Hanrahan
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 10, Houston, TX 77030, USA
    J Clin Oncol 25:4952-60. 2007
    ....
  70. doi request reprint Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2422-30. 2008
    ..The aim of the current study was to assess the prognostic value of baseline circulating tumor cells (CTCs) in a large cohort of patients with newly diagnosed metastatic breast cancer (MBC)...
  71. ncbi request reprint Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials
    Emer O Hanrahan
    Department of Breast Medical Oncology, Unit 1354, UT MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Pharmacother 6:1477-91. 2005
    ....
  72. ncbi request reprint Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  73. ncbi request reprint Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis
    Eugene H Huang
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:490-6. 2007
    ..To evaluate the locoregional efficacy of multimodality treatment for breast cancer patients who present with ipsilateral supraclavicular (SCV) disease without systemic metastases...
  74. pmc Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer
    Leonel F Hernandez-Aya
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 29:2628-34. 2011
    ..To evaluate the clinical outcomes and relationship between tumor size, lymph node status, and prognosis in a large cohort of patients with confirmed triple receptor-negative breast cancer (TNBC)...
  75. doi request reprint Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:1819-26. 2011
    ....
  76. ncbi request reprint Docetaxel for treatment of solid tumours: a systematic review of clinical data
    Alberto Montero
    Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 6:229-39. 2005
    ..Here, we review major randomised phase III trials with docetaxel in the treatment of solid malignant disease...
  77. ncbi request reprint Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
    Daniel J Booser
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, Texas 77030 4095, USA
    Cancer Chemother Pharmacol 50:6-8. 2002
    ..L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer...
  78. ncbi request reprint Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer
    Lajos Pusztai
    Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3454-61. 2003
    ..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)...
  79. ncbi request reprint Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..The purpose of this study was to analyze global gene expression changes in serial tumor core biopsy specimens taken during neoadjuvant chemotherapy for primary breast cancer...
  80. doi request reprint Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival
    Garth Beinart
    Department of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:867-74. 2007
    ..The aim of our study was to describe tumor properties, patient characteristics, and method of cancer detection for a large cohort of patients with bilateral breast cancer and to assess the associations of these factors with OS and RFS...
  81. ncbi request reprint Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:2113-22. 2006
    ..Node-negative breast cancers that are < or = 1 cm are stage T1a,bN0M0. Controversy surrounds the prognosis of these patients with locoregional therapy only and the need for adjuvant systemic therapy...
  82. ncbi request reprint Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Chemother Pharmacol 49:299-302. 2002
    ..We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil...
  83. ncbi request reprint A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer
    L Johnetta Blakely
    Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5425-31. 2004
    ..The objective of this study was to investigate the safety and the pharmacokinetics in patients with previously treated advanced breast cancer...
  84. ncbi request reprint Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer
    Alberto Montero
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Drugs R D 6:299-305. 2005
  85. ncbi request reprint Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy
    Funda Meric
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:926-33. 2003
    ....
  86. ncbi request reprint Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial
    Eduardo Bruera
    Department of Palliative Care and Rehabilitation Medicine, Unit 008, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3475-81. 2007
    ..To evaluate the effectiveness of donepezil compared with placebo in cancer patients with fatigue as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)...
  87. pmc Caregiver symptom burden: the risk of caring for an underserved patient with advanced cancer
    Guadalupe R Palos
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1070-9. 2011
    ..In this longitudinal study, the authors assessed changes in symptom severity in caregivers and underserved minority patients diagnosed with advanced solid tumors who were being treated at public hospitals...
  88. ncbi request reprint Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer Invest 20:29-37. 2002
    ..The aim of this study was to determine the MTD of vinorelbine and docetaxel given in combination with G-CSF...
  89. ncbi request reprint Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials
    Banu Arun
    Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4943-8. 2007
    ..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known...
  90. ncbi request reprint Capecitabine-induced pancreatitis
    Kellie L Jones
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Pharmacotherapy 23:1076-8. 2003
    ..Clinicians should be aware of this potential adverse effect, particularly in patients with preexisting risk factors for pancreatitis who are prescribed capecitabine...
  91. ncbi request reprint Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  92. ncbi request reprint Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  93. ncbi request reprint Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
    Silwan Chedid
    Department of Breast Medical Oncology, M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Unit 424, Houston, TX, 77030 4095, USA
    Cancer Chemother Pharmacol 57:540-4. 2006
    ..The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies...
  94. ncbi request reprint Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
    Michael S Ewer
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7820-6. 2005
    ..However, trastuzumab is associated with cardiotoxicity that has not yet been fully explored. We present our experience with patients who developed trastuzumab-related cardiotoxicity...
  95. ncbi request reprint Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial
    Eduardo Bruera
    Department of Palliative Care and Rehabilitation Medicine, Unit 0008, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:2073-8. 2006
    ..To evaluate the effectiveness of patient-controlled methylphenidate as compared with placebo in cancer patients with fatigue, as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)...
  96. ncbi request reprint HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger
    Dipen Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:900-5. 2005
    ..Although p53 and HER-2/neu overexpression are found in 30% of breast carcinomas in women of all ages and are associated with high rates of lymph node metastases, their role in women age < 30 years has not been studied extensively...
  97. doi request reprint A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects
    Steven J Kronowitz
    Department of Plastic and Reconstructive Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Plast Reconstr Surg 122:1631-47. 2008
    ..In patients undergoing a partial mastectomy, choosing the best method with which to repair the defect is essential to optimizing outcomes and minimizing the potential for postoperative complications...
  98. ncbi request reprint Pain education for underserved minority cancer patients: a randomized controlled trial
    Karen O Anderson
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, 1100 Holcombe Blvd, Box 221, Houston, TX 77030, USA
    J Clin Oncol 22:4918-25. 2004
    ..Previous studies found that African American and Hispanic cancer patients are at risk for undertreatment of pain. We evaluated the efficacy of a pain education intervention for underserved minority patients...
  99. doi request reprint Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7909-16. 2008
    ..We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC)...
  100. ncbi request reprint Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:880-8. 2002
    ..To compare the pathologic factors associated with postmastectomy locoregional recurrence (LRR) in breast cancer patients not receiving radiation who were treated with neoadjuvant chemotherapy (NEO) vs. adjuvant chemotherapy (ADJ)...
  101. ncbi request reprint Docetaxel secretion in tears: association with lacrimal drainage obstruction
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, Box 443, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Ophthalmol 120:1180-2. 2002
    ..To test the hypothesis that docetaxel may be secreted in tears after intravenous infusion...